Tau protein biomarkers
Tau protein biomarkers
Tau protein, a microtubule-associated protein predominantly found in neurons, plays a crucial role in maintaining neuronal structure and function. In neurodegenerative diseases, abnormal tau aggregation leads to the formation of neurofibrillary tangles, disrupting neuronal integrity and contributing to cognitive decline. The presence of these tau aggregates is a hallmark of several neurodegenerative disorders, collectively known as tauopathies, including Alzheimer’s disease, frontotemporal lobar degeneration, and progressive supranuclear palsy.
In Alzheimer’s disease, hyperphosphorylated tau accumulates intracellularly, forming tangles that correlate with disease severity and progression. Elevated levels of Tau protein in cerebrospinal fluid (CSF) and blood have been associated with neuronal damage and cognitive impairment, making Tau protein biomarkers for early diagnosis and monitoring of Alzheimer’s disease. Recent advancements in blood-based assays measuring phosphorylated tau isoforms, such as p-tau217, have shown high accuracy in detecting Alzheimer’s pathology, offering less invasive and more accessible diagnostic options.
Beyond Alzheimer’s disease, Tau protein biomarkers are instrumental in differentiating between various neurodegenerative disorders. For instance, distinct tau isoform patterns in CSF can help distinguish frontotemporal lobar degeneration from Alzheimer’s disease, aiding in accurate diagnosis and appropriate treatment planning. Additionally, tau imaging and quantification can provide insights into disease progression and therapeutic efficacy across different tauopathies. Ongoing research continues to explore the utility of tau biomarkers in research practice, aiming to enhance diagnostic precision and improve patient outcomes in neurodegenerative diseases.
